跳至主要内容
临床试验/ACTRN12616001697471
ACTRN12616001697471进行中(未招募)未知

Fiducial Image guided Stereotactic ablative body radiotherapy (SABR) for Hepatocellular carcinoma After Interventional Radiology treatment (TACE) (FISHAR trial)

Royal Adelaide Hospital0 个研究点目标入组 12 人开始时间: 2016年12月9日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • INCLUSION CRITERIA
  • Aged > 18 years
  • Able to give informed consent
  • Barcelona clinic liver cancer (BCLC) class A/B as determined by a Hepatocellular Carcinoma Multidisciplinary team (HCC MDT)
  • HCC diagnosed by standard radiological criteria or histology
  • HCC < 6cm which is amenable to SABR
  • Pre-treated with TACE with incomplete response or re-occurrence
  • Measureable disease on imaging defined by M RECIST criteria

排除标准

  • EXCLUSION CRITERIA
  • BCLC C (significant decompensated liver disease or HCC not amenable to TACE)
  • Significant comorbidities unable to safely tolerate sedation/anaesthetic
  • Expected life expectancy of < 24 months
  • Prior radiotherapy to abdomen
  • Pregnant or lactating (any woman of childbearing potential must have a pregnancy test prior to enrollment and must take adequate precautions to prevent pregnancy during treatment)

研究者

相似试验